Concomitant Treatment of Tuberculosis and Hepatitis C Virus in Coinfected Patients Using Serum Drug Concentration Monitoring.
Alex AshkinAfe AlexisMegan NinnemanRene Rico TresgalloDavid AshkinCharles A PeloquinPublished in: Open forum infectious diseases (2023)
These cases illustrate concomitant use of LDV/SOF and rifabutin in patients with HCV/TB coinfection. Utilizing serum drug concentration monitoring to guide dosing, correction of transaminitis were achieved, which allowed the use rifamycin-containing TB therapy. These findings suggest that concomitant therapy of TB/HCV is possible, safe, and effective.
Keyphrases
- hepatitis c virus
- mycobacterium tuberculosis
- human immunodeficiency virus
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- adverse drug
- prognostic factors
- peritoneal dialysis
- stem cells
- pulmonary tuberculosis
- mesenchymal stem cells
- patient reported
- hiv aids
- bone marrow
- combination therapy
- antiretroviral therapy